Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664333 | 0.95 | KCNH2 (0.37) | PLK1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7770555 | 0.93 | KCNH2 (0.40) | PLK1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8670473 | 0.93 | KCNH2 (0.40) | PLK1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8667845 | 0.93 | KCNH2 (0.40) | PLK1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8667928 | 0.89 | KDM4E (0.32) | KDM4EUSP2ALDH1A1POLBMAPT | |
| SCHEMBL2456293 | 0.84 | IDO1 (0.32) | KCNH2USP2 | |
| SCHEMBL2459637 | 0.78 | KCNH2 (0.39) | PLK1KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2141121 | 0.78 | HDAC3 (0.35) | KCNH2L3MBTL1 | |
| SCHEMBL6553717 | 0.76 | TSHR (0.30) | — | |
| SCHEMBL819968 | 0.76 | SKP2 (0.35) | KCNH2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1234007-B1 | OLIGOMERIC METHINE DYES | CLARIANT FINANCE BVI LTD (VG) | 2004-02-18 | — | — | EP | disclosed |
| EP-1234007-A1 | OLIGOMERIC METHINE DYES | Clariant Finance (BVI) Limited (VG) | 2002-08-28 | — | — | EP | disclosed |
| US-20010012899-A1 | Oligomeric methine dyes | CLARIANT FINANCE ( BVI) LIMITED | 2001-08-09 | — | — | US | disclosed |
| WO-2001036543-A1 | OLIGOMERIC METHINE DYES | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-05-25 | — | — | WO | disclosed |
| US-5750552-A | ANTIULCER AGENTS | ARAX CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0736527-A1 | Imadazoline derivative, possible tautomer thereof, process of manufacturing therefor, and vulnerary including such derivative or tautomer | ARAX CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-4256458-A | DIMERIC PYRIDINIUM DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012899-A1 | Oligomeric methine dyes | INMT, DDT, DDC | PLK1 4508/4885KCNH2 2336/4885KDM4E 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.